Posted by Michael Wonder on 21 Jun 2022
EQRx announces acceptance of marketing authorisation application by the UK's Medicines and Healthcare Products Regulatory Agency for aumolertinib in EGFR mutated non-small-cell lung cancer
14 June 2022 - Application is based on data from pivotal Phase 3 AENEAS trial in the first-line treatment of EGFR mutated non-small-cell lung cancer.
EQRx today announced that the United Kingdom’s MHRA has accepted for review the marketing authorisation application for aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in development for the first-line treatment of adult patients with locally advanced or metastatic non-small-cell lung cancer with activating EGFR mutations and for the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer.
